These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 1958264)
1. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Adams JD; Klaidman LK; Odunze IN; Shen HC; Miller CA Mol Chem Neuropathol; 1991 Jun; 14(3):213-26. PubMed ID: 1958264 [TBL] [Abstract][Full Text] [Related]
2. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242 [TBL] [Abstract][Full Text] [Related]
3. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. Makar TK; Nedergaard M; Preuss A; Gelbard AS; Perumal AS; Cooper AJ J Neurochem; 1994 Jan; 62(1):45-53. PubMed ID: 7903354 [TBL] [Abstract][Full Text] [Related]
4. Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Frey WH; Najarian MM; Kumar KS; Emory CR; Menning PM; Frank JC; Johnson MN; Ala TA Brain Res; 1996 Apr; 714(1-2):87-94. PubMed ID: 8861612 [TBL] [Abstract][Full Text] [Related]
5. Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Tohgi H; Abe T; Saheki M; Hamato F; Sasaki K; Takahashi S Neurosci Lett; 1995 Jan; 184(1):21-4. PubMed ID: 7739798 [TBL] [Abstract][Full Text] [Related]
6. Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. Coles LD; Tuite PJ; Öz G; Mishra UR; Kartha RV; Sullivan KM; Cloyd JC; Terpstra M J Clin Pharmacol; 2018 Feb; 58(2):158-167. PubMed ID: 28940353 [TBL] [Abstract][Full Text] [Related]
7. Circadian Disruption Reveals a Correlation of an Oxidative GSH/GSSG Redox Shift with Learning and Impaired Memory in an Alzheimer's Disease Mouse Model. LeVault KR; Tischkau SA; Brewer GJ J Alzheimers Dis; 2016; 49(2):301-16. PubMed ID: 26484899 [TBL] [Abstract][Full Text] [Related]
8. Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. Clevens RA; Beal MF Brain Res; 1989 May; 486(2):387-90. PubMed ID: 2471578 [TBL] [Abstract][Full Text] [Related]
9. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Gellhaar S; Sunnemark D; Eriksson H; Olson L; Galter D Cell Tissue Res; 2017 Sep; 369(3):445-454. PubMed ID: 28466093 [TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236 [TBL] [Abstract][Full Text] [Related]
11. Brain glutathione levels--a novel biomarker for mild cognitive impairment and Alzheimer's disease. Mandal PK; Saharan S; Tripathi M; Murari G Biol Psychiatry; 2015 Nov; 78(10):702-10. PubMed ID: 26003861 [TBL] [Abstract][Full Text] [Related]
12. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Jellinger KA Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452 [TBL] [Abstract][Full Text] [Related]
14. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Perry TL; Yong VW Neurosci Lett; 1986 Jun; 67(3):269-74. PubMed ID: 3737015 [TBL] [Abstract][Full Text] [Related]
15. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Almeida OP; Burton EJ; McKeith I; Gholkar A; Burn D; O'Brien JT Dement Geriatr Cogn Disord; 2003; 16(2):57-63. PubMed ID: 12784028 [TBL] [Abstract][Full Text] [Related]
16. The emerging role of glutathione in Alzheimer's disease. Saharan S; Mandal PK J Alzheimers Dis; 2014; 40(3):519-29. PubMed ID: 24496077 [TBL] [Abstract][Full Text] [Related]